Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vericel (VCEL) Cash & Equivalents: 2010-2025

Historic Cash & Equivalents for Vericel (VCEL) over the last 13 years, with Sep 2025 value amounting to $100.4 million.

  • Vericel's Cash & Equivalents rose 87.04% to $100.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.4 million, marking a year-over-year increase of 87.04%. This contributed to the annual value of $74.5 million for FY2024, which is 7.86% up from last year.
  • Per Vericel's latest filing, its Cash & Equivalents stood at $100.4 million for Q3 2025, which was up 24.67% from $80.5 million recorded in Q2 2025.
  • Over the past 5 years, Vericel's Cash & Equivalents peaked at $100.4 million during Q3 2025, and registered a low of $43.0 million during Q2 2023.
  • Over the past 3 years, Vericel's median Cash & Equivalents value was $62.9 million (recorded in 2024), while the average stood at $66.4 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 103.24% in 2021, then decreased by 25.26% in 2022.
  • Over the past 5 years, Vericel's Cash & Equivalents (Quarterly) stood at $68.3 million in 2021, then decreased by 25.26% to $51.1 million in 2022, then surged by 35.29% to $69.1 million in 2023, then rose by 7.86% to $74.5 million in 2024, then soared by 87.04% to $100.4 million in 2025.
  • Its Cash & Equivalents was $100.4 million in Q3 2025, compared to $80.5 million in Q2 2025 and $73.5 million in Q1 2025.